Stay updated with breaking news from Respira Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- According to Coherent Market Insights, The global Active Pharmaceutical Ingredients market was valued at US$ 235 Billion in 2023 and is...
Company plans to pursue UK authorization in parallel to approval in the U.S. Qnovia, Inc. ("Qnovia"), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement
Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery.
Qnovia, a company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary raises $17M
LOS ANGELES--(BUSINESS WIRE)--Respira Technologies, Inc.—a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases—has rebranded as “QNOVIA” and adopted Qnovia, Inc. as its corporate name. As part of the rebranding, the company has...